Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
Mengyuan Liu, Zheran Liu, Shuangshuang He, Yiyan Pei, Shihong Xu, Junyou Ge, Yan Qing, Youneng Wei, Ye Chen, Ping Ai, Xingchen Peng
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Cancer Genomics and Diagnostics · Radiomics and Machine Learning in Medical Imaging
In the published article “Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, et al. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health West Pac, 2023, 31: 100617” was not cited in the article. The citation has now been inserted in Methods, Data source, Paragraph 1 and should read:
“This study used data from an open-label, multicenter phase 2 clinical trial conducted between 2017 and 2019 at 42 hospitals in China involving 153 patients with NPC (Supplementary Figure 1) (6)”.
In the published article, there was an error in Table 1 as published. In the ECOG performance status row, the current version displays the numerical coding used for statistical modeling (i.e., 1 and 2). This should be revised to reflect the actual clinical values (ECOG = 0 and ECOG = 1), as presented to clinicians. The corrected Table 1 and its caption “Baseline characteristics of patients with and without immune-related adverse events (irAEs)” appear below.
In the published article, there was an error in Table 2 as published. A portion of the fatigue-related data was inadvertently omitted during table compilation. Upon verification, the total number of fatigue events, including Grade 1–2, should be 4. The corrected Table 2 and its caption “Incidence and severity of immune-related adverse events (irAEs) among patients” appear below.
In the published article, there was an error in Figure 4 as published. After publication, we realized that the survival curve presented in Figure 4 overlaps with data previously published by Dr. Shihong Xu in Oral Oncology (2025; https://doi.org/10.1016/j.oraloncology.2024.107161). Dr. Xu is one of our research collaborators. Although using the same database, we analysed different markers. We focused on the predictive modeling. We acknowledge that including this figure may result in unintended duplication. To maintain clarity and proper attribution, we respectfully request the removal of Figure 4 from the published article.
In the published article, there was an error in Supplementary Figure 2. Upon verification, the total number of fatigue events, including Grade 1–2, should be 4.
In the published article, there was an error. As in the case of Figure 4, we removed the sentence discussing survival analysis, which overlapped with results already reported by Dr. Shihong Xu in Oral Oncology (2025). Therefore, we do not elaborate on this point further in the current article.
A correction has been made to Discussion, Paragraph 3. This sentence previously stated:
“Further KM survival curve analysis revealed that patients who experienced irAEs had better PFS, suggesting that the occurrence of irAEs may be associated with a better treatment response (Figure 4).”
This sentence has been removed.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.